169 related articles for article (PubMed ID: 19482341)
1. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
Imberti D; Legnani C; Baldini E; Cini M; Nicolini A; Guerra M; De Paoli M; Zanardi A; Palareti G
Thromb Res; 2009 Dec; 124(6):667-71. PubMed ID: 19482341
[TBL] [Abstract][Full Text] [Related]
2. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).
Imberti D; Baldini E; Pierfranceschi MG; Nicolini A; Cartelli C; De Paoli M; Boni M; Filippucci E; Cariani S; Bottani G
Obes Surg; 2014 Feb; 24(2):284-91. PubMed ID: 24163189
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis of thromboembolism in bariatric surgery with parnaparin.
Forestieri P; Quarto G; De Caterina M; Cuocolo A; Pilone V; Formato A; Ruocco A; Ferrari P
Obes Surg; 2007 Dec; 17(12):1558-62. PubMed ID: 18004632
[TBL] [Abstract][Full Text] [Related]
5. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
6. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
PRIME CARE Study Investigators Group
Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
[TBL] [Abstract][Full Text] [Related]
10. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
[TBL] [Abstract][Full Text] [Related]
11. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
[TBL] [Abstract][Full Text] [Related]
13. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin.
Montebugnoli M; Bugamelli S; Calò P; Zangheri E; Ferrari P
Clin Appl Thromb Hemost; 2007 Jul; 13(3):249-58. PubMed ID: 17636187
[TBL] [Abstract][Full Text] [Related]
15. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of low molecular weight heparin during and after aortic and carotid surgery: dose finding study.
Alimi YS; Juhan C; Barthelemy P; Boudier JL; Pansart M; Boutin B; De Moro S
Panminerva Med; 1996 Mar; 38(1):15-21. PubMed ID: 8766874
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
Douketis JD; Kinnon K; Crowther MA
Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
[TBL] [Abstract][Full Text] [Related]
18. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery.
Magee CJ; Barry J; Javed S; Macadam R; Kerrigan D
Surg Obes Relat Dis; 2010; 6(3):322-5. PubMed ID: 20510295
[TBL] [Abstract][Full Text] [Related]
19. Laboratory evaluation of the effect of prophylaxis for thromboembolism with fractionated heparin in patients undergoing laparoscopic cholecystectomy.
Martínez Ramos C; López Pastor A; Núñez Peña JR; Ruiz de Gopegui M; Sanz López R; Jorgensen T; Pastor L; Tamames S
Rev Esp Enferm Dig; 2000 Jan; 92(1):27-35. PubMed ID: 10749595
[TBL] [Abstract][Full Text] [Related]
20. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
